Figure S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Year: 2026
Type: other
Abstract: The CAR T-cell maximal expansion (CMax) and area under the curve from day 0 to 28 (AUC0-28) for CAR19 and CAR22 following CAR19 or CAR22 infusion in the same patient. (A) Analysis by flow cytometry. (B) Analysis by qPCR assay. No statistical comparison was performed due to the limited number of patients.
Authors: Yi-Jiun Su, Anne Marijn Kramer, Mark P. Hamilton, Neha Agarwal, Hrishikesh K. Srinagesh, John H. Baird, Bita Sahaf, Adam Kuo, Zachary J. Ehlinger, Moksha H. Desai, Skyler P. Rietberg, Ramya Tunuguntla, Shabnum Patel, Harshini Chinnasamy, Nikolaos Gkitsas-Long, Dorota D. Klysz, Annie Kathleen Brown, Sushma Bharadwaj, Saurabh Dahiya, Melody Smith, Lori Muffly, Crystal L. Mackall, Zinaida Good, Steven A. Feldman, David B. Miklos, Matthew J. Frank
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164992911